MethodHub Software Shares Up 5% on Strategic AI Partnership with Datafoundry

Synopsis: MethodHub Software Limited has entered into a strategic partnership with Datafoundry to deliver AI-driven pharmacovigilance and pharma-tech solutions for global pharmaceutical and life sciences companies. The collaboration is expected to strengthen the company’s presence in the rapidly growing healthcare technology and AI automation market.

Shares of MethodHub Software Limited are likely to remain in focus after the company announced a strategic partnership with Datafoundry, an AI/ML-focused SaaS provider, to strengthen its artificial intelligence-driven pharmacovigilance (PV) and pharma-tech offerings for global pharmaceutical, biotechnology, and life sciences enterprises. The stock gained nearly 4 percent following the announcement.

MethodHub Software Limited has a total market capitalization of approximately Rs. 164.50 crore. The company’s shares were trading at Rs. 87.25 apiece on the stock exchange, up by 4.99 percent. The stock has gained 9.27 percent over the last five trading sessions, while it has declined 3.07 percent over the last month. The stock touched a 52-week high of Rs. 172 and a 52-week low of Rs. 63.

According to the company’s exchange filing, the collaboration combines MethodHub’s expertise in pharmacovigilance operations, regulatory compliance, and global service delivery with Datafoundry’s AI-powered platforms, including Safety AI, Signal AI, and Literature Monitor. These solutions automate safety case management, signal detection, literature surveillance, and regulatory reporting, enabling pharmaceutical companies to improve efficiency, compliance, and patient safety.

The partnership comes at a time when pharmacovigilance is becoming increasingly important due to rising regulatory scrutiny, growing drug safety requirements, and the increasing complexity of global clinical and post-market surveillance. By integrating AI and machine learning into pharmacovigilance workflows, the companies aim to help customers transition from manual processes to intelligent, automated, and scalable safety operations that comply with global regulatory standards, including FDA and EMA guidelines.

MethodHub will continue providing end-to-end pharmacovigilance services such as adverse event processing, aggregate reporting, signal detection, quality assurance, and audit readiness. These capabilities will now be enhanced through Datafoundry’s AI platforms, enabling faster case processing, improved data accuracy, reduced false positives, multilingual literature monitoring, and better regulatory compliance. The company also plans to leverage its proprietary AI-powered recruitment platform, QuantumHire, to help clients efficiently build specialized pharmacovigilance teams.

The collaboration aligns with the broader trend of digital transformation across the global pharmaceutical industry. Drug manufacturers are increasingly investing in AI, automation, cloud technologies, and advanced analytics to improve operational efficiency, reduce compliance risks, accelerate regulatory reporting, and strengthen patient safety. The growing adoption of AI-powered pharmacovigilance platforms is expected to create significant long-term opportunities for technology service providers operating in the healthcare sector.

For investors, the strategic alliance strengthens MethodHub’s positioning in the high-growth life sciences technology market. Expanding its AI-enabled pharmacovigilance capabilities could enhance its service portfolio, deepen relationships with global pharmaceutical clients, and support long-term revenue growth as demand for intelligent healthcare technology solutions continues to increase.

Incorporated in 2016, MethodHub Software Limited is an Information Technology (IT) services provider specializing in cloud engineering, data and AI, cybersecurity, ERP/CRM integration, and digital transformation solutions. The company serves more than 40 global clients with a team of over 500 professionals, while expanding its presence in life sciences, healthcare technology, and pharmacovigilance services.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses arising from decisions based on this article. Please consult your investment advisor before investing

The post MethodHub Software Shares Up 5% on Strategic AI Partnership with Datafoundry appeared first on Trade Brains.